219 related articles for article (PubMed ID: 20859453)
1. New and emerging treatment approaches to lupus.
Haubitz M
Biologics; 2010 Sep; 4():263-71. PubMed ID: 20859453
[TBL] [Abstract][Full Text] [Related]
2. Exploring new territory: the move towards individualised treatment.
Haubitz M
Lupus; 2007; 16(3):227-31. PubMed ID: 17432112
[TBL] [Abstract][Full Text] [Related]
3. B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis-Role in Pathogenesis and Effect of Immunosuppressive Treatments.
Yap DYH; Chan TM
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835612
[TBL] [Abstract][Full Text] [Related]
4. [What's new in internal medicine: emerging treatments for systemic lupus erythematosus].
Hachulla É
Ann Dermatol Venereol; 2011 Dec; 138 Suppl 4():S241-4. PubMed ID: 22202645
[TBL] [Abstract][Full Text] [Related]
5. Drugs in early clinical development for Systemic Lupus Erythematosus.
Postal M; Sinicato NA; Appenzeller S; Niewold TB
Expert Opin Investig Drugs; 2016; 25(5):573-83. PubMed ID: 26950689
[TBL] [Abstract][Full Text] [Related]
6. Targeted B-cell depletion therapy in childhood-onset systemic lupus erythematosus: progress to date.
Marks SD; Tullus K
Paediatr Drugs; 2007; 9(6):371-8. PubMed ID: 18052407
[TBL] [Abstract][Full Text] [Related]
7. [Progress in B-cell targeting therapy for the treatment of systemic lupus erythematosus].
Tanaka Y
J UOEH; 2011 Jun; 33(2):173-81. PubMed ID: 21702122
[TBL] [Abstract][Full Text] [Related]
8. Biologics in SLE: the current status.
Rajadhyaksha AG; Mehra S; Nadkar MY
J Assoc Physicians India; 2013 Apr; 61(4):262-7. PubMed ID: 24482965
[TBL] [Abstract][Full Text] [Related]
9. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
10. Novel and emerging drugs for systemic lupus erythematosus: mechanism of action and therapeutic activity.
Robak E; Robak T
Curr Med Chem; 2012; 19(3):438-53. PubMed ID: 22335517
[TBL] [Abstract][Full Text] [Related]
11. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
12. Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study).
Yan Q; Du F; Kang Y; Ye P; Wang X; Xu J; Tang J; Wang N; Jiang G; Li Z; Wang X; Xue Q; Huang X; Zhang X; Zhou Y; Dai M; Bao C
Trials; 2021 Aug; 22(1):530. PubMed ID: 34380536
[TBL] [Abstract][Full Text] [Related]
13. An unusual case of systemic lupus erythematosus, lupus nephritis, and transient monoclonal gammopathy.
Strobel ES; Fritschka E; Schmitt-Gräff A; Peter HH
Rheumatol Int; 2000; 19(6):235-41. PubMed ID: 11063295
[TBL] [Abstract][Full Text] [Related]
14. Current role of rituximab in systemic lupus erythematosus.
Mok CC
Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
[TBL] [Abstract][Full Text] [Related]
15. Treatment for lupus nephritis.
Henderson L; Masson P; Craig JC; Flanc RS; Roberts MA; Strippoli GF; Webster AC
Cochrane Database Syst Rev; 2012 Dec; 12():CD002922. PubMed ID: 23235592
[TBL] [Abstract][Full Text] [Related]
16. Update οn the diagnosis and management of systemic lupus erythematosus.
Fanouriakis A; Tziolos N; Bertsias G; Boumpas DT
Ann Rheum Dis; 2021 Jan; 80(1):14-25. PubMed ID: 33051219
[TBL] [Abstract][Full Text] [Related]
17. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
Staveri C; Karokis D; Liossis SC
Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of the phosphatase JKAP/DUSP22 in T cells as a potential new biomarker of systemic lupus erythematosus nephritis.
Chuang HC; Chen YM; Hung WT; Li JP; Chen DY; Lan JL; Tan TH
Oncotarget; 2016 Sep; 7(36):57593-57605. PubMed ID: 27557500
[TBL] [Abstract][Full Text] [Related]
19. Treatment for lupus nephritis.
Flanc RS; Roberts MA; Strippoli GF; Chadban SJ; Kerr PG; Atkins RC
Cochrane Database Syst Rev; 2004; (1):CD002922. PubMed ID: 14973998
[TBL] [Abstract][Full Text] [Related]
20. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
